Key facts
- This page summarizes Dominic Rodrigues's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Jul 2024, 17:20.
Dominic Rodrigues - 25 Jun 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- PRESIDENT, Director
- Issuer ticker
- PVCT
- Reported as of
- 25 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jul 2024, 17:20:06 UTC
- Prior SEC filing
- 20 Sep 2022
- Next SEC filing
- 30 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dominic Rodrigues
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dominic Rodrigues filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 23 Jul 2024.
Change
- Previous filing in this sequence was filed on 20 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVCT
transaction
Derivative
Series D Convertible Preferred Stock
Disposed to Issuer
- Transaction value
- $0
- Shares
- -11,416,242
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,416,242
- Exercise price
- Footnotes
- F1, F2, F3
PVCT
transaction
Derivative
Series D-1 Convertible Preferred Stock
Award
- Transaction value
- $0
- Shares
- +1,141,626
- Change %
- Price
- $0.000000
- Shares after
- 1,141,626
- Date
- 25 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,416,260
- Exercise price
- Footnotes
- F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each share of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Convertible Preferred Stock") is convertible into one share of the Issuer's common stock, par value $0.001 per share ("Common Stock").
Footnote F2
On June 25, 2024, 11,416,242 shares of Series D Convertible Preferred Stock held by the Reporting Person were converted into 1,141,626 shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock"), pursuant to that certain Conversion Agreement, dated June 21, 2024, by and between the Reporting Person and the Issuer.
Footnote F3
The Series D Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D Convertible Preferred Stock.
Footnote F4
Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's Common Stock.
Footnote F5
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.